Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;15(1):39-46.
doi: 10.1007/s11906-012-0318-z.

The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases

Affiliations

The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases

Jiandong Zhang et al. Curr Hypertens Rep. 2013 Feb.

Abstract

The renin-angiotensin system plays a critical role in the pathogenesis of several cardiovascular diseases, largely through activation of type I angiotensin (AT(1)) receptors by angiotensin II. Treatment with AT(1) receptor blockers (ARBs) is a proven successful intervention for hypertension and progressive heart and kidney disease. However, the divergent actions of AT(1) receptors on individual cell lineages in hypertension may present novel opportunities to optimize the therapeutic benefits of ARBs. For example, T lymphocytes make important contributions to the induction and progression of various cardiovascular diseases, but new experiments indicate that activation of AT(1) receptors on T cells paradoxically limits inflammation and target organ damage in hypertension. Future studies should illustrate how these discrepant functions of AT(1) receptors in target organs versus mononuclear cells can be exploited for the benefit of patients with recalcitrant hypertension and other cardiovascular diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosure No potential conflicts of interest relevant to this article were reported.

Figures

Figure 1
Figure 1. Verification of T cell-specific deletion of the type 1a angiotensin (AT1A) receptor in T cell knockout (KO) mice
A, Representative histology of thymus, spleen, and kidney in CD4-Cre+ mT/mG and control (CD4 Cre mT/mG) mice. In these mT/mG mice, green fluorescence indicates the presence of CD4 Cre expression whereas red fluorescence indicates the absence of CD4 Cre expression. Blue fluorescence in kidney is a nuclear DAPI stain. B, Splenocytes were harvested from T cell WT and T cell KO littermates and sorted into 3 subpopulations. Agtr1a mRNA expression was quantitated in these purified immune cell populations and in kidney and heart from T cell WT and T cell KO groups (n≥6). This method revealed a 90% deletion of the AT1A receptor from both CD4+ and CD8+ T lymphocytes in the T cell KO animals. * P < 0.00001 vs. T cell WT. (Adapted from Zhang et al. [40])
Figure 1
Figure 1. Verification of T cell-specific deletion of the type 1a angiotensin (AT1A) receptor in T cell knockout (KO) mice
A, Representative histology of thymus, spleen, and kidney in CD4-Cre+ mT/mG and control (CD4 Cre mT/mG) mice. In these mT/mG mice, green fluorescence indicates the presence of CD4 Cre expression whereas red fluorescence indicates the absence of CD4 Cre expression. Blue fluorescence in kidney is a nuclear DAPI stain. B, Splenocytes were harvested from T cell WT and T cell KO littermates and sorted into 3 subpopulations. Agtr1a mRNA expression was quantitated in these purified immune cell populations and in kidney and heart from T cell WT and T cell KO groups (n≥6). This method revealed a 90% deletion of the AT1A receptor from both CD4+ and CD8+ T lymphocytes in the T cell KO animals. * P < 0.00001 vs. T cell WT. (Adapted from Zhang et al. [40])

Similar articles

Cited by

References

    1. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of reninangiotensin system blockade. Am J Cardiol. 2010;105:10A–20A. - PubMed
    1. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82–C97. - PubMed
    1. Crowley SD, Tharaux PL, Audoly LP, et al. Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand. 2004;181:561–570. - PubMed
    1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. - PubMed
    1. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553. - PubMed

Publication types

MeSH terms

Substances